Lixte Biotechnology Holdings Inc (LIXT)
2.79
-0.17
(-5.74%)
USD |
NASDAQ |
May 07, 16:00
2.86
+0.07
(+2.51%)
After-Hours: 20:00
Lixte Biotechnology Holdings SG&A Expense (Quarterly): 0.8768M for Dec. 31, 2023
SG&A Expense (Quarterly) Chart
Historical SG&A Expense (Quarterly) Data
Date | Value |
---|---|
December 31, 2023 | 0.8768M |
September 30, 2023 | 0.8917M |
June 30, 2023 | 1.242M |
March 31, 2023 | 1.181M |
December 31, 2022 | 1.179M |
September 30, 2022 | 1.206M |
June 30, 2022 | 1.381M |
March 31, 2022 | 1.196M |
December 31, 2021 | 1.221M |
September 30, 2021 | 1.010M |
June 30, 2021 | 1.470M |
March 31, 2021 | 1.282M |
December 31, 2020 | 0.6926M |
September 30, 2020 | 0.8023M |
June 30, 2020 | 0.2554M |
March 31, 2020 | 0.2925M |
December 31, 2019 | 0.204M |
September 30, 2019 | 0.5138M |
June 30, 2019 | 0.5478M |
March 31, 2019 | 0.3904M |
December 31, 2018 | 0.3815M |
September 30, 2018 | 1.031M |
June 30, 2018 | 0.3308M |
March 31, 2018 | 0.3541M |
December 31, 2017 | 0.3293M |
Date | Value |
---|---|
September 30, 2017 | 0.2575M |
June 30, 2017 | 0.2773M |
March 31, 2017 | 0.4774M |
December 31, 2016 | 0.3656M |
September 30, 2016 | 0.3111M |
June 30, 2016 | 0.2381M |
March 31, 2016 | 0.1521M |
December 31, 2015 | 0.1388M |
September 30, 2015 | 0.1553M |
June 30, 2015 | 0.2137M |
March 31, 2015 | 0.2466M |
December 31, 2014 | 0.3583M |
September 30, 2014 | 0.1923M |
June 30, 2014 | 0.1816M |
March 31, 2014 | 0.553M |
December 31, 2013 | 0.1142M |
September 30, 2013 | 0.0932M |
June 30, 2013 | 0.12M |
March 31, 2013 | 0.1676M |
December 31, 2012 | 0.148M |
September 30, 2012 | 0.4445M |
June 30, 2012 | 0.1828M |
March 31, 2012 | 0.3183M |
December 31, 2011 | 0.1854M |
September 30, 2011 | 0.1349M |
SG&A Expense Definition
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
SG&A Expense (Quarterly) Range, Past 5 Years
0.204M
Minimum
Dec 2019
1.470M
Maximum
Jun 2021
0.9182M
Average
1.010M
Median
Sep 2021
SG&A Expense (Quarterly) Benchmarks
iBio Inc | 2.961M |
PAVmed Inc | 11.72M |
PDS Biotechnology Corp | 2.941M |
Moleculin Biotech Inc | 2.252M |
Syros Pharmaceuticals Inc | 5.888M |